(Q36696923)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

title

Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

main subject

metastatic breast cancer

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Paolo Bruzzi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Valentina Guarneri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Pierfranco Conte

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

author name string

C Orlandini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

B Salvadori

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

S Donati

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

E Landucci

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

M Rondini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

S Ricci

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

language of work or name

English

0 references

publication date

1 March 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

24 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

volume

90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

page(s)

962-967

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

24 November 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Reporting results of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410217

Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy

5 September 2018

1 reference

12 December 2020

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

1 reference

12 December 2020

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines

1 reference

12 December 2020

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

1 reference

12 December 2020

Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group

1 reference

12 December 2020

[Prognostic factors in the response of a first line chemotherapy in advanced breast cancer]

1 reference

12 December 2020

Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy

1 reference

12 December 2020

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

1 reference

12 December 2020

Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601634

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14997190%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

PubMed publication ID

14997190

1 reference